➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Dow
Merck
AstraZeneca
McKinsey

Last Updated: April 16, 2021

DrugPatentWatch Database Preview

Methylprednisolone - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for methylprednisolone and what is the scope of patent protection?

Methylprednisolone is the generic ingredient in eleven branded drugs marketed by Pfizer, Duramed Pharms Barr, Heather, Invatech, Jubilant Cadista, Lupin Ltd, Novast Labs, Par Pharm, Sandoz, Sungen Pharma, Tianjin Tianyao, Vintage Pharms, Watson Labs, Zydus Pharms, Pharmacia And Upjohn, Bel Mar, Akorn, Amneal, Sagent Pharms Inc, Sandoz Inc, Teva Pharms Usa, Abbott, Hospira, Hospira Inc, Elkins Sinn, Organon Usa Inc, Abraxis Pharm, Aurobindo Pharma Ltd, Bedford Labs, Fresenius Kabi Usa, Hikma, Intl Medication, and Teva Parenteral, and is included in eighty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are forty drug master file entries for methylprednisolone. Thirty suppliers are listed for this compound.

Drug Prices for methylprednisolone

See drug prices for methylprednisolone

Drug Sales Revenue Trends for methylprednisolone

See drug sales revenues for methylprednisolone

Recent Clinical Trials for methylprednisolone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Geneva FoundationN/A
United States Department of DefenseN/A
Johns Hopkins UniversityN/A

See all methylprednisolone clinical trials

Pharmacology for methylprednisolone
Medical Subject Heading (MeSH) Categories for methylprednisolone

US Patents and Regulatory Information for methylprednisolone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa METHYLPREDNISOLONE SODIUM SUCCINATE methylprednisolone sodium succinate INJECTABLE;INJECTION 040612-001 Aug 12, 2004 AP RX No No   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn MEDROL ACETATE methylprednisolone acetate OINTMENT;TOPICAL 012421-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Jubilant Cadista METHYLPREDNISOLONE methylprednisolone TABLET;ORAL 040189-003 Jul 20, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Lupin Ltd METHYLPREDNISOLONE methylprednisolone TABLET;ORAL 209097-002 Feb 22, 2019 DISCN No No   Start Trial   Start Trial   Start Trial
Sungen Pharma METHYLPREDNISOLONE methylprednisolone TABLET;ORAL 212262-001 Jun 27, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Colorcon
Mallinckrodt
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.